DGX Quest Diagnostics
NYSE · SEC CIK 1022079 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $37.31M 23 sales by 8 insiders
- Filings on record
- 341 since 2021-07-06, latest 2026-09-03 17:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Davis J. E. | CEO, Pres, Dir | — | $17.08M |
| Doherty Catherine T. | EVP, Regional Businesses | — | $6.96M |
| PREVOZNIK MICHAEL E | SVP, GC | — | $6.69M |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | — | $2.17M |
| Plewman Patrick | SVP for Diagnostic Services | — | $2.03M |
| DELANEY MARK E | SVP, Chief Commercial Off | — | $1.86M |
| PFEIFFER GARY M | Dir | — | $270.3K |
| Gregg Vicky B | Dir | — | $239.7K |
| Lassiter Wright III | Dir | — | — |
| Deppe Michael J | SVP, CAO, Corp. Ctrl | — | — |
Transactions 434
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-31 | 2025-01-29 | DGX | SAMAD SAM | EVP, CFO | L - Small Acq | $158.04 | +35 | 17.5K | +0.2% | +$5,531 | |
| DM | 2024-12-02 | 2024-11-27 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale+OE | $162.99 | -33.1K | 96.7K | -26% | -$5.40M |
| D | 2024-12-02 | 2024-11-27 | DGX | Doherty Catherine T. | EVP, Regional Businesses | M - OptEx | $103.57 | +33.1K | 101.5K | +48% | +$3.43M |
| D | 2024-12-02 | 2024-11-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $86.63 | +35.1K | 73.6K | +91% | +$3.04M |
| DM | 2024-12-02 | 2024-11-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $163.07 | -35.1K | 38.5K | -48% | -$5.73M |
| DM | 2024-11-07 | 2024-11-06 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | M - OptEx | $68.66 | +18.8K | 43.6K | +76% | +$1.29M |
| DM | 2024-11-07 | 2024-11-06 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | S - Sale+OE | $154.04 | -18.8K | 34.9K | -35% | -$2.89M |
| 2024-10-30 | 2024-10-28 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale | $156.92 | -1,775 | 9,734 | -15% | -$278.5K | |
| 2024-10-25 | 2024-10-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | L - Small Acq | $149.37 | +60 | 16.3K | +0.4% | +$8,962 | |
| 2024-10-25 | 2024-10-21 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $149.39 | +4 | 5,023 | +0.1% | +$597.56 | |
| 2024-10-25 | 2024-10-21 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L - Small Acq | $149.37 | +21 | 11.5K | +0.2% | +$3,137 | |
| 2024-10-25 | 2024-10-21 | DGX | Gregg Vicky B | Dir | L - Small Acq | $149.37 | +76 | 18.0K | +0.4% | +$11.4K | |
| 2024-10-25 | 2024-10-21 | DGX | SAMAD SAM | EVP, CFO | L - Small Acq | $149.37 | +37 | 17.5K | +0.2% | +$5,527 | |
| 2024-09-26 | 2024-09-24 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $155.70 | -120 | 4,673 | -3% | -$18.7K | |
| D | 2024-09-03 | 2024-08-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale+OE | $154.97 | -32.6K | 38.5K | -46% | -$5.04M |
| D | 2024-09-03 | 2024-08-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | M - OptEx | $95.80 | +32.6K | 71.0K | +85% | +$3.12M |
| 2024-08-29 | 2024-08-28 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale | $153.26 | -1,990 | 11.5K | -15% | -$305.0K | |
| 2024-08-16 | 2024-08-14 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $149.46 | -74 | 13.4K | -0.5% | -$11.1K | |
| 2024-07-26 | 2024-07-22 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | L - Small Acq | $146.97 | +31 | 13.5K | +0.2% | +$4,556 | |
| 2024-07-26 | 2024-07-24 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | S - Sale | $143.08 | -420 | 5,019 | -8% | -$60.1K | |
| 2024-07-26 | 2024-07-22 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $146.98 | +6 | 5,439 | +0.1% | +$881.88 | |
| 2024-07-26 | 2024-07-22 | DGX | Gregg Vicky B | Dir | L - Small Acq | $146.97 | +77 | 18.0K | +0.4% | +$11.3K | |
| 2024-07-26 | 2024-07-22 | DGX | SAMAD SAM | EVP, CFO | L - Small Acq | $146.97 | +21 | 17.5K | +0.1% | +$3,086 | |
| 2024-07-26 | 2024-07-22 | DGX | Plewman Patrick | SVP for Diagnostic Services | L - Small Acq | $146.97 | +60 | 16.2K | +0.4% | +$8,818 | |
| 2024-07-18 | 2024-07-16 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $142.65 | -3,910 | 17.4K | -18% | -$557.8K | |
| 2024-05-20 | 2024-05-16 | DGX | PFEIFFER GARY M | Dir | A - Grant | $0.00 | +1,482 | 28.9K | +5% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | MORRISON DENISE M | Dir | A - Grant | $0.00 | +1,482 | 9,490 | +19% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | Doi Tracey | Dir | A - Grant | $0.00 | +1,482 | 5,183 | +40% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | Gregg Vicky B | Dir | A - Grant | $0.00 | +1,482 | 17.9K | +9% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | CARTER ROBERT B | Dir | A - Grant | $0.00 | +1,482 | 1,482 | New | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | MAIN TIMOTHY L | Dir | A - Grant | $0.00 | +1,482 | 25.1K | +6% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | Lassiter Wright III | Dir | A - Grant | $0.00 | +1,482 | 7,709 | +24% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +1,482 | 27.8K | +6% | $0 | |
| 2024-05-20 | 2024-05-16 | DGX | Diaz Luis | Dir | A - Grant | $0.00 | +1,482 | 2,851 | +108% | $0 | |
| 2024-05-01 | 2024-04-29 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale | $140.00 | -1,760 | 13.4K | -12% | -$246.4K | |
| 2024-04-26 | 2024-04-22 | DGX | Gregg Vicky B | Dir | A - Grant | $126.24 | +81 | 16.4K | +0.5% | +$10.2K | |
| 2024-04-26 | 2024-04-22 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $126.25 | +24 | 21.4K | +0.1% | +$3,030 | |
| 2024-04-26 | 2024-04-22 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $126.25 | +69 | 16.1K | +0.4% | +$8,711 | |
| 2024-04-26 | 2024-04-22 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $126.25 | +45 | 15.2K | +0.3% | +$5,681 | |
| 2024-03-28 | 2024-03-26 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $128.11 | -114 | 16.0K | -0.7% | -$14.6K | |
| 2024-03-28 | 2024-03-26 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $128.11 | -170 | 5,433 | -3% | -$21.8K | |
| M | 2024-03-01 | 2024-02-28 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $126.36 | -273 | 15.2K | -2% | -$34.5K |
| M | 2024-03-01 | 2024-02-28 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $126.36 | -333 | 16.2K | -2% | -$42.1K |
| 2024-03-01 | 2024-02-28 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $126.36 | -656 | 21.3K | -3% | -$82.9K | |
| 2024-03-01 | 2024-02-28 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | F - Tax | $126.36 | -225 | 5,603 | -4% | -$28.4K | |
| M | 2024-03-01 | 2024-02-28+ | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $126.45 | -6,744 | 68.4K | -9% | -$852.8K |
| M | 2024-03-01 | 2024-02-28 | DGX | Doherty Catherine T. | EVP, Regional Businesses | F - Tax | $126.36 | -1,201 | 75.7K | -2% | -$151.8K |
| 2024-03-01 | 2024-02-28 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $126.36 | -262 | 4,793 | -5% | -$33.1K | |
| M | 2024-03-01 | 2024-02-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $126.36 | -861 | 44.5K | -2% | -$108.8K |
| 2024-03-01 | 2024-02-29 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $125.88 | -5,611 | 38.5K | -13% | -$706.3K | |
| M | 2024-03-01 | 2024-02-28 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $126.36 | -5,020 | 126.0K | -4% | -$634.3K |
| M | 2024-03-01 | 2024-02-28 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $126.36 | -109 | 34.9K | -0.3% | -$13.8K |
| 2024-02-27 | 2024-02-23 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $125.02 | -869 | 16.4K | -5% | -$108.6K | |
| 2024-02-27 | 2024-02-23 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $125.02 | +2,388 | 17.3K | +16% | +$298.5K | |
| 2024-02-27 | 2024-02-23 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $125.02 | -6,525 | 131.0K | -5% | -$815.8K | |
| 2024-02-27 | 2024-02-23 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $125.02 | +13.4K | 137.5K | +11% | +$1.67M | |
| 2024-02-27 | 2024-02-23 | DGX | Doherty Catherine T. | EVP, Regional Businesses | F - Tax | $125.02 | -3,757 | 76.4K | -5% | -$469.7K | |
| 2024-02-27 | 2024-02-23 | DGX | Doherty Catherine T. | EVP, Regional Businesses | A - Grant | $125.02 | +9,314 | 80.1K | +13% | +$1.16M | |
| 2024-02-27 | 2024-02-23 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $125.02 | +7,569 | 47.8K | +19% | +$946.3K | |
| 2024-02-27 | 2024-02-23 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $125.02 | -2,825 | 45.0K | -6% | -$353.2K | |
| 2024-02-27 | 2024-02-23 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $125.02 | -631 | 35.0K | -2% | -$78.9K | |
| 2024-02-27 | 2024-02-23 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | A - Grant | $125.02 | +1,689 | 35.7K | +5% | +$211.2K | |
| 2024-02-27 | 2024-02-23 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $125.02 | -619 | 15.4K | -4% | -$77.4K | |
| 2024-02-27 | 2024-02-23 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $125.02 | +2,039 | 16.0K | +15% | +$254.9K | |
| 2024-02-23 | 2024-02-23 | DGX | Gregg Vicky B | Dir | S - Sale | $126.64 | -2,500 | 16.3K | -13% | -$316.6K | |
| 2024-02-23 | 2024-02-21 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | F - Tax | $125.02 | -89 | 34.0K | -0.3% | -$11.1K | |
| 2024-02-23 | 2024-02-21 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $125.02 | -407 | 40.9K | -1.0% | -$50.9K | |
| 2024-02-23 | 2024-02-22 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $126.14 | -661 | 40.2K | -2% | -$83.4K | |
| 2024-02-23 | 2024-02-21 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $125.02 | -102 | 14.0K | -0.7% | -$12.8K | |
| 2024-02-23 | 2024-02-21 | DGX | Plewman Patrick | SVP for Diagnostic Services | F - Tax | $125.02 | -139 | 14.9K | -0.9% | -$17.4K | |
| 2024-02-23 | 2024-02-22 | DGX | Doherty Catherine T. | EVP, Regional Businesses | S - Sale | $126.14 | -821 | 70.8K | -1% | -$103.6K | |
| 2024-02-23 | 2024-02-21 | DGX | Doherty Catherine T. | EVP, Regional Businesses | F - Tax | $125.02 | -493 | 71.6K | -0.7% | -$61.6K | |
| 2024-02-23 | 2024-02-21 | DGX | Davis J. E. | CEO, Pres, Dir | F - Tax | $125.02 | -762 | 124.1K | -0.6% | -$95.3K | |
| D | 2024-02-16 | 2024-02-14 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $0.00 | +2,348 | 5,828 | +67% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $0.00 | +5,478 | 22.0K | +33% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | DEPPE MICHAEL J | SVP, CAO, Corp. Ctrl | A - Grant | $0.00 | +558 | 34.1K | +2% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | Doherty Catherine T. | SVP, Regional Businesses | A - Grant | $0.00 | +4,304 | 72.1K | +6% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | A - Grant | $0.00 | +2,250 | 5,055 | +80% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $0.00 | +2,446 | 15.0K | +19% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | Davis J. E. | CEO, Pres, Dir | A - Grant | $0.00 | +22.3K | 124.9K | +22% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $0.00 | +2,935 | 41.3K | +8% | $0 |
| D | 2024-02-16 | 2024-02-14 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $0.00 | +2,641 | 14.1K | +23% | $0 |
| 2024-02-02 | 2024-01-31 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $129.33 | +29 | 11.4K | +0.3% | +$3,751 | |
| 2024-02-02 | 2024-01-31 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $129.33 | +17 | 16.5K | +0.1% | +$2,199 | |
| 2024-02-02 | 2024-01-31 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $129.33 | +50 | 12.6K | +0.4% | +$6,467 | |
| 2024-02-02 | 2024-01-31 | DGX | Gregg Vicky B | Dir | A - Grant | $129.33 | +88 | 18.8K | +0.5% | +$11.4K | |
| 2023-10-26 | 2023-10-23 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $122.84 | +52 | 12.5K | +0.4% | +$6,388 | |
| 2023-10-26 | 2023-10-23 | DGX | SAMAD SAM | EVP, CFO | A - Grant | $122.86 | +18 | 16.5K | +0.1% | +$2,211 | |
| 2023-10-26 | 2023-10-23 | DGX | Gregg Vicky B | Dir | A - Grant | $122.86 | +92 | 18.7K | +0.5% | +$11.3K | |
| 2023-10-26 | 2023-10-23 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $122.86 | +30 | 11.4K | +0.3% | +$3,686 | |
| 2023-09-27 | 2023-09-25 | DGX | GARDNER MARK A | SVP of Molecular Gen, Oncol | F - Tax | $126.22 | -116 | 2,805 | -4% | -$14.6K | |
| 2023-08-17 | 2023-08-15 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | F - Tax | $135.23 | -74 | 11.3K | -0.7% | -$10.0K | |
| 2023-07-27 | 2023-07-25 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | A - Grant | $144.59 | +25 | 11.4K | +0.2% | +$3,615 | |
| 2023-07-27 | 2023-07-25 | DGX | Gregg Vicky B | Dir | A - Grant | $144.59 | +78 | 18.6K | +0.4% | +$11.3K | |
| 2023-07-27 | 2023-07-25 | DGX | Plewman Patrick | SVP for Diagnostic Services | A - Grant | $144.59 | +44 | 12.4K | +0.4% | +$6,362 | |
| 2023-07-17 | 2023-07-14 | DGX | SAMAD SAM | EVP, CFO | F - Tax | $140.18 | -3,909 | 16.5K | -19% | -$548.0K | |
| 2023-05-19 | 2023-05-17 | DGX | RING TIMOTHY M | Dir | A - Grant | $0.00 | +1,369 | 25.7K | +6% | $0 | |
| 2023-05-19 | 2023-05-17 | DGX | Gregg Vicky B | Dir | A - Grant | $0.00 | +1,369 | 18.6K | +8% | $0 | |
| 2023-05-19 | 2023-05-17 | DGX | Lassiter Wright III | Dir | A - Grant | $0.00 | +1,369 | 6,092 | +29% | $0 | |
| 2023-05-19 | 2023-05-17 | DGX | MORRISON DENISE M | Dir | A - Grant | $0.00 | +1,369 | 7,955 | +21% | $0 |
Purchase Sale Sale after option exercise All abbreviations